Nanosphere, Inc.'s Verigene Gram-Positive Blood Culture Test Demonstrates High Sensitivity and Specificity for a Broad Panel of Bacterial Targets

NORTHBROOK, Ill., Sept. 19, 2011 (GLOBE NEWSWIRE) -- Nanosphere’s (Nasdaq:NSPH) Verigene BC-GP test, based on the company’s proprietary array-based nanoparticle technology, demonstrated 100% sensitivity and specificity for detection of the drug-resistant bacteria MRSA and VRE, and an overall sensitivity of 98.4% for a broad panel of bacterial targets, according to an initial study.